Phase II/III CRO Benchmarking—Small Pharma Market (3rd Ed.)

Report Overview

Industry Standard Research understands the desire for a deeper dive regarding the small and emerging biopharma landscape. Are the needs, perceptions, and interactions of this segment different compared to the wider audience of Phase II/III clinical development outsourcers? In a word, yes. The goal, therefore, of this small and emerging biopharma report is two-fold. First, this research will help small and emerging biopharma companies make more informed CRO selection decisions. Second, these findings will help CROs optimize operational and marketing strategies to better accommodate small and emerging biopharma companies. As these companies continue to increase their role in drug development and innovation, we at ISR know the importance of keeping a pulse on this subset. Our goal remains the same – provide quality market research to ensure both sponsors and providers can glean what they need to make the best decisions possible for their clinical development programs and service offerings.

What you will learn:

Small & Emerging Sponsors:

• Learn how your peers at small and emerging sponsor companies select their CROs, including key CRO attributes they evaluate, prevalence of PPAs, and the use of outside consultants for CRO selection advice
• Discover how others at small sponsors evaluate CROs in terms of their personal preference and cost perceptions. Read their rationale for assigning CRO satisfaction scores to further understand how they assess their experiences with service providers

Service Providers:

• Refine your marketing efforts by focusing on what customers say makes an organization stand out to small and emerging biopharma companies
• Uncover the factors influencing small and emerging sponsor outsourcing preferences, and which factors are increasing in importance for future outsourcing
   

Major Topics:

• Service Provider Selection Process
• Service Provider Perceptions and Interactions
• Study Data
• Demographics